novel
coronaviru
ewli
emerg
humaninfectiousc
oronaviru
cov
origin
aw
uhan
seafoodm
arket
quickli
spread
beyondc
hina
th
diagnos
case
confirm
death
xinhua
news
pathogenesi
viru
yet
understood
treatment
option
avail
healthcar
profession
fight
epidem
front
line
prais
need
given
chines
research
act
quickli
isol
sequenc
viru
avail
viru
genom
sequenc
genbanki
makesi
tpossibl
identifi
treatmentsa
lthough
essenti
develop
vaccin
small
molecul
biolog
therapeut
specif
target
viru
unlik
effort
made
moment
benefitp
atient
current
outbreak
share
equenc
identityw
ith
sever
acut
espiratori
syndromerel
coronaviru
sarscov
g
enbank
id
n
equenc
identityin
everalessenti
enzym
see
figur
therefor
learnedf
rom
sever
medicin
chemistri
studi
sarscov
middl
east
respiratori
syndrom
merscov
mayb
ed
irectli
use
help
us
treat
ov
reli
spike
protein
bind
ah
ost
cellsurfac
receptor
fore
ntri
figur
ti
se
vident
receptor
angiotensinconvert
viru
entri
host
cell
posit
genom
rna
attach
directli
hostr
ibosom
translat
two
larg
cotermin
polyprotein
process
proteolysi
compon
packag
new
virion
two
proteas
particip
proteolysi
process
coronaviru
main
proteinas
andt
papainlik
proteas
plpro
order
replic
rna
genom
cov
encod
ar
eplicas
rnadepend
rna
polymeras
rdrp
four
protein
essentialf
pathogen
therapeut
current
target
spike
rdrp
plpro
possibl
treatment
nt
viewpoint
shall
analyz
similar
spike
rdrp
plpro
protein
sarscov
nd
suggest
possibl
prevent
treatment
option
compound
discussedw
ill
experiment
compound
drug
candid
ar
eview
repurpos
drug
treat
coronavirus
virus
ee
li
et
al
littl
known
far
virul
viru
shall
also
discuss
interact
spike
might
challenget
current
view
less
virul
sarscov
owe
weaker
interact
spike
sarscov
encod
al
arg
aa
aa
spike
protein
sequenc
ident
protein
two
origin
al
arg
variationexist
nterminu
figur
spike
protein
two
region
sarscov
ar
eceptor
bind
domain
rbd
nt
region
interact
current
trajectori
outbreak
unknown
p
ublic
health
medicin
measur
neededt
oc
ontain
spread
viru
optim
patient
outcom
although
littl
known
viru
examin
genom
sequenc
show
strong
homolog
betterstudi
cousin
sarscovt
spike
protein
use
host
cell
infect
show
key
nonsynonym
mutat
might
hamper
efficaci
previous
develop
therapeut
butr
emain
av
iabl
target
develop
biologicsa
nd
macrocycl
peptid
key
drug
target
includ
rnadependentr
na
polymeras
coronaviru
main
proteinas
share
trikingli
high
homolog
sarscovh
erein
suggest
four
potenti
drug
candid
peptid
ovel
vinylsulfon
proteas
inhibitor
could
use
treat
patient
suffer
ea
lso
summar
previou
effort
drug
target
hope
help
develop
broadspectrum
anticoronavir
agent
futur
epidem
sequenc
align
amino
acid
sarscov
spike
rbd
domain
conserv
pink
arrow
nonconserv
black
arrow
mutationsa
highlightedg
ray
hydrophob
aliphat
orang
n
eutrala
romat
yellow
thiol
sulfid
green
hydroxi
red
b
asic
blue
carboxyl
acid
brown
p
rimari
amid
pink
p
rolin
b
variou
bind
interact
pike
protein
pink
blue
pike
protein
homolog
modelb
uilt
use
model
base
uponpdb
e
zoom
view
sever
spike
interact
depict
b
residuesb
efor
forward
slash
refer
amino
acid
slash
refer
correspond
ident
sarscov
chembiochem
wwwchembiochemorg
high
affinityt
current
assumpt
also
engag
rbd
bind
entri
human
host
cell
align
rbd
two
origin
show
equenc
ident
figur
howev
mani
nonconserv
mutationst
hat
interactd
irectli
accumul
two
structuralregion
igur
crystal
cryoem
tructur
sarscov
complex
pdb
ajf
show
region
nd
ngage
hydrogen
bond
hydrophob
interact
mani
residu
two
region
replac
lead
al
oss
interact
also
predict
rbd
interactsw
ith
weakli
sarscov
rbd
howev
b
oth
region
highli
loop
structur
larg
variat
two
region
inevit
lead
structur
rearrang
potenti
novel
possibl
even
strongeri
nteract
region
almost
similar
sequenc
two
viru
origin
howev
tisprematur
presum
protein
fold
way
interact
assum
region
fold
way
sarscov
place
right
posit
engag
strong
hydrophob
interact
figur
interact
exist
sar
complex
due
significantli
smaller
positiona
nother
residu
potenti
engag
strong
hydrogenbond
interact
correct
distanc
engag
ar
earrang
figur
region
criticalr
esidu
sarscov
replac
owev
p
ap
rolin
ak
nown
econdarystructur
disruptor
se
xpect
lead
tructuralr
earrangemento
fr
egion
nt
sarscov
rbd
combin
new
hydrogenbond
interact
might
involv
residu
could
form
figur
anoth
notabl
differ
sarscov
rbd
sarscov
thisi
saresidu
middl
concav
rbd
bind
surfac
involv
interact
sarscov
anda
howev
long
posit
charg
couldp
otenti
engag
strong
hydrogen
bond
saltbridg
interact
respect
n
figur
although
molecular
simul
may
use
analyz
thesep
ossibl
interact
detail
u
ncertainti
persist
structur
complex
determin
crystallographi
cryoem
given
urgenc
matter
mustb
em
ultipl
research
group
work
hope
see
result
within
hort
time
altern
rbd
could
express
affin
toward
could
independ
determin
biochem
compar
sarscov
rbd
solid
experiment
resultsa
avail
claimsa
bout
weaker
bindingo
ft
rbd
towarda
sarscov
rbd
prematur
role
sarscov
spike
protein
receptor
bind
membran
fusion
make
ideal
target
forv
accin
antivir
develop
develop
sar
vaccin
base
spike
protein
summar
sever
previou
review
sever
trategi
includ
liveattenu
sarscov
k
ill
sarscov
na
vaccinesa
nd
viral
vector
vaccin
success
use
vaccin
anim
sarscov
similar
idea
could
appli
vaccin
altern
approach
directli
use
rbd
combin
immunitypromot
adjuv
av
accin
trigger
human
bodi
develop
antibodi
rbd
therebi
neutral
viru
although
publish
resultsa
bout
therapeut
antibodiesa
nd
peptid
develop
neutral
sarscov
spike
protein
expectedt
oh
ave
littl
use
neutral
sd
iscuss
two
engag
region
spike
rbd
bindinga
differ
sarscov
ntibodi
peptid
target
two
region
sarscov
rbd
expect
interact
weaklyw
itht
rbd
novel
antibodi
therapeut
peptid
interact
potent
rbd
use
block
interact
everalr
esearch
group
nclude
develop
method
build
macrocycl
peptidel
ibrariesa
nd
applyingt
hem
quick
identif
macrocycl
peptid
ligandsf
drug
target
applic
librari
search
potent
ligandsfor
rbd
two
peptid
region
potenti
lead
rapid
discoveri
macrocycl
peptid
although
group
initi
effort
lengthi
drugdiscoveri
process
make
possibl
help
patient
current
epidem
waylearn
studi
sarscov
aposs
altern
direct
use
peptid
deriv
rbd
peptid
deriv
sarscov
rbd
develop
novel
therapeut
sarscov
infect
block
arscov
bind
exampl
ap
eptid
overlap
rbd
sequenc
aa
specif
block
bind
sarscov
rbd
inhibitt
entri
sarscov
vero
cellsw
itha
ni
c
mm
onep
eptid
compris
two
motif
aa
nd
link
glycin
exhibit
potent
antisar
activ
ic
valu
mm
potent
therapeut
neutral
interact
avail
ap
ossibl
quick
solut
blockingt
interact
use
rbdbase
peptid
cocktail
thereof
although
sarscov
share
equenc
ident
genom
rna
level
rdrp
protein
share
remark
equenc
ident
figur
rdrp
involv
av
eri
larg
deepg
roov
activ
site
polymer
rna
residu
show
variat
sarscov
rdrp
mostli
distal
activ
site
figur
high
sequenc
conserv
two
enzym
makesi
tv
eri
likelyt
hat
potent
agent
develop
sarscov
rdrp
exhibit
equal
potenc
efficaci
rdrp
although
extens
chembiochem
wwwchembiochemorg
explor
everala
gents
xist
target
sarscov
rdrp
catalyz
polymer
process
one
compound
found
show
antivir
activ
aurintricarboxyl
acid
ata
f
igur
atai
sa
na
nionic
polym
shown
bind
varieti
protein
target
includ
fh
demonstr
prevent
sarscov
replic
ic
mg
ml
despit
comput
modelsv
alid
known
atat
arget
predict
rdrp
bound
target
experiment
evid
demonstr
relationship
beyond
except
remainingr
drp
inhibitor
nucleosid
analogu
nd
provid
promisinga
venu
toward
disrupt
viral
rna
replic
nucleosid
analogu
ribavirin
rbv
f
igur
test
sarscov
sarsand
mersinfect
patient
best
efficaci
rbv
inconclus
studi
show
aw
orsen
patient
outcom
review
stockman
et
al
exonucleas
activ
enzym
shown
abl
remov
mismatch
well
incorpor
nucleosid
analogu
inactiv
xonucleas
activ
shown
wwwchembiochemorg
increaset
efficaci
nucleosid
like
rbv
order
develop
nucleosid
analogu
effect
inhibit
viral
rna
replic
nucleosid
must
either
evad
detect
exonucleas
must
outcompet
exonucleas
activityr
emdesivir
excel
exampl
lattera
na
denosin
analogu
prodrug
nitril
display
potent
efficaci
sar
mer
human
airway
epitheli
hae
cell
model
mice
ic
mm
sarscov
merscov
r
espect
nh
ae
broadspectrum
activ
variou
bat
coronavirus
also
demonstr
suscept
cov
remdesivir
shown
increas
strain
inactiv
exonucleas
activ
cov
resist
remdesivir
studi
model
bcoronaviru
murin
hepatitisv
iru
mhv
mhv
passag
presenceo
ft
parent
nucleosid
contain
hydroxi
group
instead
ap
hosphoramid
develop
two
mutat
rdrp
mutat
confer
increasei
nr
esist
remdesivir
mhv
ixfold
increas
resist
homolog
mutat
introduc
rdrp
sarscov
vs
mm
mice
infect
resist
arscov
significantli
lower
lung
viral
titer
postinfect
altogeth
r
emdesivirh
shown
outcompetet
proofread
abil
mutat
confer
resist
attenu
virul
effort
towardsd
rug
coronaviru
rdrp
manner
provid
ab
asi
develop
therapeuticsf
b
ut
could
provid
broadspectrum
antiviralsus
futur
cov
outbreak
plpro
plpro
two
proteas
process
polypeptid
translat
product
genom
rna
structur
nonstructur
protein
componentsv
ital
replic
packag
ew
gener
virus
plpro
also
serv
ad
eubiquitinas
function
deubiquityl
host
cell
protein
interferon
regulatori
factor
well
inactiv
pathway
nuclear
factor
klightchainenhanc
activ
bcell
nfkb
lead
immun
suppressioni
nt
cell
host
infect
viru
proteas
vital
viru
replic
control
host
cell
viabl
target
antivir
agent
similart
ot
rdrp
protein
sarscov
share
ar
emark
equenc
ident
decod
figur
natur
form
ad
imer
monom
containst
wo
region
ntermin
catalyt
region
ctermin
region
figur
residu
catalyt
region
display
variat
figur
sequenc
align
amino
acid
andth
sarscov
conserv
pink
arrow
nonconserv
black
arrow
mutationsa
highlightedg
ray
hydrophob
aliphat
orang
n
eutrala
romat
yellow
thiol
sulfid
green
hydroxi
red
b
asic
blue
carboxyl
acid
brown
primari
amid
pink
prolin
b
model
use
model
base
sarscov
structur
pdb
green
catalyt
domain
first
monomer
unit
red
ctermin
domain
first
monomer
unit
cyan
econd
monomer
unit
c
altern
view
predict
monomer
structur
colorcod
secondarystructur
bound
azapeptid
inhibitor
show
conserv
pink
nonconserv
black
mutat
shown
residuesb
efor
forward
slash
refer
amino
acid
slash
refer
correspond
ident
sarscov
chembiochem
wwwchembiochemorg
two
origin
protein
surfac
although
sarscov
might
possibl
interactw
ith
either
substrat
inhibitor
bind
activ
site
small
structur
chang
osi
expect
interfer
significantli
bind
smallmolecul
inhibitor
activ
site
figur
smallmolecul
agent
potent
inhibit
sarscov
expect
function
similarli
towardt
unlik
plpro
two
origin
share
equenc
ident
figur
residu
variat
betweent
two
origin
cover
almost
surfac
plpro
substanti
variat
amino
acid
composit
expect
influenc
two
plpro
enzym
interact
ligand
howev
three
secondarystructur
compon
form
activ
site
vari
two
plpro
protein
figur
possibl
inhibitor
develop
sarscov
plpro
would
also
work
plpro
last
two
decad
much
research
drug
sarscov
focusedo
nt
develop
smallmolecul
peptid
peptidomimet
inhibitor
nd
plpro
mani
inhibitor
micromolar
rang
term
bind
inhibit
two
proteas
howev
lownmrang
inhibitor
identifi
use
combin
proteaseinhibitor
therapi
help
combat
viru
purposeo
ft
section
inhibitor
divid
categori
base
proteas
inhibit
stop
viru
take
controlo
f
host
cell
compound
test
term
sarscov
amerscov
radeubiquityl
cell
model
ever
hundr
small
molecul
develop
inhibit
plpro
h
owev
hese
potent
sinc
earli
classificationsw
ith
structur
inhibitori
concentr
summar
figur
compoundsa
lowmm
rang
term
inhibit
leav
room
furtherd
evelop
howev
e
xtensiv
sar
studi
alreadi
perform
finalstag
product
guid
research
know
substitu
modifi
target
summari
also
guid
research
health
profession
use
combin
therapi
two
thesec
ompound
alreadi
done
term
treat
peopl
suffer
ac
ov
infectiono
ne
compound
highlight
figur
ic
valu
against
arscov
nm
potenc
could
adequ
combat
nd
plpro
cysteinep
roteas
herefor
covalenti
nhibitor
high
potenc
could
potenti
develop
for
pecif
target
recent
immon
andc
owork
develop
ac
lass
potentialc
ovalentc
ystein
proteas
inhibitor
specif
target
cov
entri
direct
relationship
plpro
drawn
h
owev
class
vinylsulfon
small
molecul
abl
inhibit
replic
viru
nanomolar
rang
simmon
group
discov
inhibit
serin
proteas
use
camostat
well
figur
sequenc
align
amino
acid
plpro
sarscov
plpro
conserv
pink
arrow
nonconserv
black
arrow
mutationsa
highlightedg
ray
hydrophob
aliphat
orang
n
eutrala
romat
yellow
thiol
sulfid
green
hydroxi
red
b
asic
blue
carboxyl
acid
brown
primari
amid
pink
prolin
b
crystal
structur
sarscov
plpro
complex
ubiquitin
aldehyd
pdb
chembiochem
wwwchembiochemorg
cystein
proteas
use
vinylsulfon
proteas
inhibitor
abl
combat
arscovt
surviv
mice
suffer
sarscov
weret
reat
combin
therapi
significantli
increas
comparison
control
group
group
studi
sever
variat
vinylsulfon
small
molecul
shown
correspond
ic
valu
figur
compound
c
vinylsulfon
smallm
olecul
provid
addit
scaffold
sar
develop
also
test
specif
plpro
order
elucid
specif
mechan
action
given
high
potenc
sarscov
ti
sp
ossibl
equal
potent
distantm
ember
orthocoronavina
subfamili
also
provid
inspir
new
therapeut
regimen
studi
done
felin
coronaviru
fcov
mutat
form
f
elin
infecti
periton
viru
fipv
peptidyl
bisulfitea
dduct
figur
found
potent
inhibitor
fipv
replic
mm
ff
ipv
sarscov
share
sequenc
ident
b
ut
overal
structur
conserv
fretbaseda
ctiviti
assay
ic
valu
gainst
recombin
sar
found
time
fipv
vs
mm
r
espect
combin
al
ow
compound
cytotox
cc
mm
cc
mm
crfk
cell
respect
maskedaldehyd
warhead
investig
efficaci
soon
possibl
figur
arepresent
top
cov
proteas
inhibitor
provid
ascaffold
perform
sar
studi
termsofdesign
novel
smallmolecul
proteas
inhibitor
potent
inhibitor
ish
ighlight
conclus
sarscov
sharev
eri
high
sequenc
identityi
n
rdrp
rotein
previou
work
hasr
esult
discoveryo
fs
ome
potent
smallmolecul
therapeut
base
two
protein
sarscovw
ee
nvision
remdesivir
could
directli
appli
treat
sr
emdesivir
ad
rug
undergo
ac
linic
trial
author
china
could
negoti
gilead
possibl
use
drug
patient
suffer
potenti
mallmolecul
therapeut
molecul
shown
figur
nd
spike
rbd
significantli
differ
sarscov
spike
rbd
especi
two
region
bind
differ
effect
rule
use
previous
develop
antibodi
therapeut
peptid
sarscov
spike
rbd
howev
aposs
quick
solut
inhibitt
interact
prevent
infect
use
peptid
deriv
rbd
cocktail
thereof
